Status:
UNKNOWN
Pilot Study: Comparison of Patients' Knowledge of Direct Oral Anticoagulants in Post-hospitalization Between 2 Cardiology Departments Offering or Not a Pharmaceutical Interview During Hospitalization
Lead Sponsor:
Direction Centrale du Service de Santé des Armées
Conditions:
Atrial Fibrillation
Deep Vein Thrombosis
Eligibility:
All Genders
18+ years
Brief Summary
Direct oral anticoagulants (Rivaroxaban, Apixaban and Dabigatran) are an alternative to anti-vitamin K drugs and low molecular weight heparins in many cardiovascular diseases. This new class of antic...
Eligibility Criteria
Inclusion
- Patient hospitalized for more than 48 hours in a cardiology department with a discharge prescription for curative anticoagulation.
- Indication for a direct oral anticoagulant for atrial fibrillation, deep vein thrombosis or pulmonary embolism
Exclusion
- Patients treated for the prevention of venous thromboembolic disease who have undergone scheduled total hip replacement or total knee replacement surgery.
- Patient with cognitive impairment
- Patients with a previous prescription for a direct oral anticoagulant
Key Trial Info
Start Date :
January 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT04674202
Start Date
January 18 2021
End Date
January 1 2024
Last Update
September 30 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Intercommunal de Montreuil
Montreuil, France, 93100
2
Hôpital d'Instruction des Armées Bégin
Saint-Mandé, France, 94160